Physician profile
Garry J Brown
NPI 1043366925
$1,575.12
in general payments reported to CMS, 2019-2025
32 companies · $78.58 in 2025
The $78.58 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $591 · 2021: $251 · 2022: $83.41 · 2023: $57.30 · 2024: $98.97 · 2025: $78.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $230.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $160.34 | 2020-2025 | Imfinzi |
| Janssen Biotech, INC. | $144.41 | 2019-2020 | |
| Amgen INC. | $127.99 | 2019-2022 | |
| Seagen INC. | $92.43 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $77.28 | 2020-2021 | |
| Genzyme Corporation | $75.58 | 2019-2021 | |
| Eisai INC. | $75.19 | 2019 | |
| Puma Biotechnology, INC. | $53.25 | 2020-2024 | |
| Abbvie INC. | $46.74 | 2021-2024 | |
| Incyte Corporation | $42.86 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $36.51 | 2019 | |
| Merck Sharp & Dohme LLC | $35.98 | 2023-2024 | Keytruda |
| Beigene USA, INC. | $31.13 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.68 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $30.27 | 2021-2022 | |
| Dova Pharmaceuticals | $29.19 | 2020 | |
| Dendreon Pharmaceuticals LLC | $26.59 | 2021 | |
| Celgene Corporation | $23.82 | 2020 | |
| Tersera Therapeutics LLC | $23.38 | 2023 | Zoladex |
| Acceleron Pharma, INC. | $21.78 | 2020 | |
| Taiho Oncology, INC. | $16.47 | 2019 | |
| Astellas Pharma US INC | $16.10 | 2019 | |
| Pfizer INC. | $16.09 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.90 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.80 | 2023 | Iclusig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.67 | 2024 | Gilotrif |
| Advanced Accelerator Applications | $13.65 | 2020 | |
| Emd Serono, INC. | $13.56 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $13.46 | 2020 | |
| Agios Pharmaceuticals, INC. | $12.03 | 2020 | |
| Lilly USA, LLC | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garry Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.